Aprea Therapeutics Inc. (APRE)

NASDAQ: APRE · Real-Time Price · USD

1.66

-0.09 (-5.14%)

At close: Apr 29, 2025, 3:40 PM

Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.

Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics Inc.

Country	United States
IPO Date	Oct 3, 2019
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Dr. Oren Gilad Ph.D.

Contact Details

Address: 535 Boylston St. Boston, Massachusetts United States
Website	https://atrinpharma.com

Stock Details

Ticker Symbol	APRE
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001781983
CUSIP Number	03836J102
ISIN Number	US03836J2015
Employer ID	00-0000000
SIC Code	2834

Key Executives

Name	Position
Dr. Oren Gilad Ph.D.	Co-Founder, Chief Executive Officer, President & Director
Andrea Epstein	Controller
Brian Wiley	Senior Vice President of Corporate Development & Strategy
Dr. Lars B. Abrahmsen Ph.D.	Senior Vice President & Chief Scientific Officer
Dr. Michel Afargan Ph.D.	Head of Pharmacology Development
Ze'ev Weiss B.Sc., C.P.A.	Chief Business Advisor

Latest SEC Filings

Date	Type	Title
Apr 22, 2025	ARS	Filing
Apr 22, 2025	DEFA14A	Filing
Apr 22, 2025	DEF 14A	Filing
Apr 08, 2025	SCHEDULE 13G/A	[Amend] Filing
Apr 04, 2025	4	Filing
Mar 31, 2025	4	Filing
Mar 31, 2025	4	Filing
Mar 25, 2025	10-K	Annual Report
Mar 25, 2025	8-K	Current Report
Feb 13, 2025	SCHEDULE 13G/A	[Amend] Filing

View All SEC Filings

Advertisement